Ligand id: 9202

Name: BPS-804

1. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. (2006)
Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
J. Bone Miner. Res., 21 (11): 1738-49. [PMID:17002572]
2. Kneissel M, Halleux C, Hu S-I, Diefenbach-Streiber B, Prassler J. (2009)
Compositions and methods for use for antibodies against sclerostin.
Patent number: WO2009047356. Assignee: Novartis Ag. Priority date: 12/08/2007. Publication date: 16/04/2009.
3. Lewiecki EM. (2014)
Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.
Ther Adv Musculoskelet Dis, 6 (2): 48-57. [PMID:24688605]
4. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R et al.. (2009)
Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
J. Bone Miner. Res., 24 (4): 578-88. [PMID:19049336]
5. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. (2005)
Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
J. Biol. Chem., 280 (20): 19883-7. [PMID:15778503]
6. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K et al.. (2010)
Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
J. Bone Miner. Res., 25 (5): 948-59. [PMID:20200929]